ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0623

Rheumatoid Synovial Fibroblasts Display Imprinted Memory of Their Synovial Endotype Which Can Be Plastically Modulated by B-cells Crosstalk

Edoardo Prediletto1, Cankut Cubuk2, Elena Pontarini3, Felice Rivellese2, Alessandra Nerviani2, Davide Lucchesi3, Mattia Caliste1, Elisa Corsiero1, Manzoor Ahmed3, rebecca hands3, Myles Lewis2, Costantino Pitzalis2 and Michele Bombardieri4, 1Wlliam Harvey Research Institute Queen Mary University on London, London, United Kingdom, 2Queen Mary University of London, London, United Kingdom, 3William Harvey Research Institute, London, United Kingdom, 4Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University, London, United Kingdom

Meeting: ACR Convergence 2022

Keywords: B-Lymphocyte, Biologicals, cytokines, Fibroblasts, Synovial, rheumatoid arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: RA – Etiology and Pathogenesis Poster

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: Despite advances in the treatment of Rheumatoid Arthritis (RA), synthetics and biologicals drugs are ineffective in ~40% of patients. The origin of this refractoriness is unclear, but several clues point at the synovial microenvironment (SE) and the relative cellular heterogeneity between patients. Indeed, the crosstalk between stromal and immune cells within the rheumatoid joints is critical for the perpetuation of chronic inflammation and autoimmunity. We previously described the existence of different RA endotypes such as the lympho-myeloid, LM, which is B-cell rich and the fibroid-paucimmune, FPI, which – on the other hand – is devoid of B-cells. In line with this, it is currently uncertain whether the different presence of cells subsets – particularly of synovial fibroblasts (SFs) – derived from different RA endotypes is driven by “imprinted” properties of the SFs or is shaped by the SE through interactions with infiltrating immune cells (or whether these differences account for any pharmacological resistance). We hypothesized that trough the comparison of freshly isolated SFs and primary established SFs cultures obtained from LM vs FPI RA synovial biopsies we would find the existence of both “imprinted” and “inducible” RASFs signatures.

Methods: We performed flowcytometry analysis and single cell RNA sequencing (sc-RNAseq) on SFs obtained from LM and FPI biopsies, in isolation or in co-culture with RA B cells. Next, supernatant has been screened trough Multiplex and ELISA. Furthermore, we compared our results to publicly available sc-RNAseq datasets on freshly isolated SFs and to our bulk-RNAseq data from clinical trials patients.

Results: Hierarchical clustering from sc-RNAseq transcriptional profiling of LM vs FPI RASF – after several cell passages – identified profoundly different gene signatures: whereby LM-RASF were characterised by genes involved in inflammation (IFI27/GAS6/CCL2/IL1R1), proteoglycan formation (LUM/DCN) and integrin binding (CD9/VCAM1/FBLN1), FPI-RASF were defined by genes such as ATF5, IGFBP5, CLEC3B as well as genes related to collagen biosynthesis (COL1A1/COL5A1). We speculate that cultured primary LM and FPI SFs identified footprints are probably reflecting their original tissue microenvironment. Also, these signatures can be partially tracked in larger clinical patient’s database of whole tissue bulk RNA-seq in both early arthritis and established RA. Finally, the modulation of FPI related genes following B-cell depletion identified poor responders to Rituximab in the R4RA randomised clinical trial. Strikingly, RA B-cells co-cultured with FPI-RASF over 14 days profoundly altered the FPI-RASF transcriptional profile including the ex-novo expression of genes typical of LM-RASF.

Conclusion: Our work shows that RASFs from different pathotypes bear different features, which are maintained in culture. Also, this imprinted memory can be dynamically modulated by the presence of B cells and can influence response/resistance to targeted biologic therapies. This work is particularly interesting in the context of refractory RA for a possible therapeutic exploitation.

Supporting image 1

Fig1: Graphical abstract of the project; Fig 2: Graphical abstract of the working hypothesis

Supporting image 2

Fig3: Heatmap showing comparison of LM RASFs (top, blue) and FPI RASFs (bottom, green) differentially expressed genes.
Fig4: Volcano Plot showing comparison of LM RASFs (Left) and FPI RASFs (right) genes with magnitude of changes and significance (Nonsignificant genes: grey; Adjusted p-value: blue: adjusted p-value and log2 fold change: red, filled triangle: -log10 Adjusted p-value<300, empty triangles: -log10 Adjusted p-value>300).
Fig5: A: UMAP showing Control (Ctrl, alone cultured cells) and co-cultured SFs merged a re-clustered. B: Violin plot of CCL2 and ADAMTS5 expression between LM and FPI. Wilcoxon Test. C: Dot-plot on bulk RNAseq on freshly sorted SFs obtained from Accelerating Medicines Partnership (AMP, https://immunogenomics.io/ampra/  Defining Inflammatory Cell States in Rheumatoid Arthritis Joint Synovial Tissues by Integrating Single-cell Transcriptomics and Mass Cytometry, Zhang et al, Nature Immunology, 2019) comparing CCL2 andADAMTS5 expression on leukocyte-poor and rich RA ( AMP representation of our FPI and LM classification relatively). Values are expressed by fold change (Log2(TPM+1) transcript por Million). Kruskal Wallis.

Supporting image 3

Fig 6: A: STRING analysis showing relative interactome of LM RASFs (right ) and FPI RASFs (left) DEGs. Genes “rescued” in FPI RASFs after coculture have been highlighted in red. B: Volcano plot showing upregulation of rescued genes from figure C in FPI RASFs co-cultured with B cells relatively FPI FPI RASFs ctrl. Nonsignificant genes: grey; Adjusted p-value: blue, log2 fold change: green, adjusted p-value and log2 fold change: red, filled grey triangle: -log10 Adjusted p-value<300.

Fig 7: A: Comparison LM RASFs (blue) and FPI RASFs (green) violin plots before and after B lymphocytes coculture, showing increase of CCL2 and rescue in FPI RASFs. B: MCP1/CCL2 concentration at day 2 in supernatants from Co-culture LM and FPI RASFs showing higher concentration in LM RASFs. Unpaired T test. Unpaired T test; MCP1/CCL2 concentration at day 2 in supernatants from Ctrl LM and co-cultured LM RASFs showing higher concentration in the latter. Unpaired T test; MCP1/CCL2 concentration at day 2 in supernatants from Ctrl FPI and co-cultured FPI RASFs showing higher concentration in the latter. Unpaired T test;

Fig 8: A: Summary box-plots on bulk RNA seq obtained from Early RA PEAC cohort, showing increased presence of FPI signature in the fibroid pathotype patients. Wilcoxon rank-sum test (also known as Manon-Whitney test); Summary box-plots on bulk RNA seq obtained from DMARDs inadequate response (PEAC cohort 6 months) showing increased presence of FPI signature in the fibroid pathotype patients. Wilcoxon rank-sum test (also known as Manon-Whitney) test); Summary box-plots on bulk RNA seq obtained from TNFi inadequate response (R4RA cohort), showing increased presence of FPI signature in the fibroid pathotype patients. Wilcoxon rank-sum test (also known as Manon-Whitney test). B: single FPI gene expression between baseline and 16 weeks in rituximab treated patients of R4RA showing increase of the gene in the non-responders regarding the RTX DAS28 ESR EULAR response.


Disclosures: E. Prediletto, None; C. Cubuk, None; E. Pontarini, None; F. Rivellese, None; A. Nerviani, None; D. Lucchesi, None; M. Caliste, None; E. Corsiero, None; M. Ahmed, None; r. hands, None; M. Lewis, None; C. Pitzalis, AbbVie/Abbott, Astellas, Astra-Zeneca/MedImmune, BMS, CelGene, Grunenthal, GSK, Johnson/J&J, Kiniksa, MSD, Pfizer, Sanofi, Roche/Genentech/Chugai, UCB; M. Bombardieri, Amgen, Janssen, GlaxoSmithKlein(GSK), UCB.

To cite this abstract in AMA style:

Prediletto E, Cubuk C, Pontarini E, Rivellese F, Nerviani A, Lucchesi D, Caliste M, Corsiero E, Ahmed M, hands r, Lewis M, Pitzalis C, Bombardieri M. Rheumatoid Synovial Fibroblasts Display Imprinted Memory of Their Synovial Endotype Which Can Be Plastically Modulated by B-cells Crosstalk [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/rheumatoid-synovial-fibroblasts-display-imprinted-memory-of-their-synovial-endotype-which-can-be-plastically-modulated-by-b-cells-crosstalk/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/rheumatoid-synovial-fibroblasts-display-imprinted-memory-of-their-synovial-endotype-which-can-be-plastically-modulated-by-b-cells-crosstalk/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology